Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy

被引：0
|
作者：
Luo, F. [1 ]
Liu, Y. Y. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; liver dysfunction; hepatopathy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-73
引用
收藏
页码：S671 / S672
页数：2
相关论文
共 50 条
  • [21] Prognostic Value of Clinical, Immune and Biochemical Markers in EGFR-Mutant NSCLC Patients Treated with First-Line EGFR TKIs
    Ng, I.
    Kumarakulasinghe, N.
    Syn, N.
    Teng, R.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2208 - S2209
  • [22] Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG 51403
    Goldberg, Sarah
    Moon, James
    Lilenbaum, Rogerio
    Politi, Katerina
    Melnick, Mary Ann
    Stinchcombe, Thomas
    Horn, Leora
    Chen, Everett
    Miao, Jieling
    Redman, Mary
    Kelly, Karen
    Gandara, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1220 - S1221
  • [23] Phase II study of erlotinib plus onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
    Sakai, Hiroshi
    Kishi, Kazuma
    Seto, Takashi
    Kozuki, Toshiyuki
    Nishio, Makoto
    Imamura, Fumio
    Nokihara, Hiroshi
    Satouchi, Miyako
    Tahata, Takashi
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
  • [24] The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
    Chen, Kuan-Chih
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    ONCOTARGETS AND THERAPY, 2023, 16 : 317 - 326
  • [25] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [26] Optimal first-line therapy for NSCLC with EGFR mutations
    Joel W. Neal
    Lecia V. Sequist
    Nature Reviews Clinical Oncology, 2010, 7 : 71 - 72
  • [27] First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs
    Lu, X.
    Wang, J.
    Wang, C.
    Bi, N.
    Zhou, Z.
    Wang, Y.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S892 - S892
  • [28] The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC
    Chen, D.
    Chu, T.
    Chang, Q.
    Zhang, Y.
    Xiong, L.
    Qiao, R.
    Teng, J.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [29] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
    Estevinho, F.
    Felizardo, M.
    Fernandes, G.
    Figueiredo, A.
    Lopes, A.
    PULMONOLOGY, 2019, 25 (05): : 306 - 309
  • [30] Antacid and de novo brain metastases in EGFR-mutant NSCLC patients treated with first-line, first-generation EGFR-TKIs
    Chen, Y-M.
    Lin, M-C.
    Lai, C-H.
    Fang, W-F.
    Chang, H-C.
    Wang, C-C.
    Tseng, C-C.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S132 - S132
12345